Abstract
Purpose
To identify the predictive role of pretreatment skeletal muscle mass index (SMI) for long-term survival of bladder cancer patients.
Methods
Several databases were searched for studies investigating the relationship between pretreatment SMI and prognosis in bladder cancer. The overall survival (OS) and cancer-specific survival (CSS) were defined as primary and secondary outcomes, respectively. Hazard ratios (HRs) and 95% confidence intervals (CIs) were combined.
Results
Nine studies involving 1476 cases were included. The results demonstrated that a lower pretreatment SMI was significantly related to poorer OS (HR = 1.56, 95% CI: 1.33–1.82, P<0.001) and subgroup analysis based on thresholds of SMI revealed similar results. Besides, pretreatment SMI was also obviously related to CSS (HR = 1.75, 95% CI: 1.36–2.25, P<0.001).
Conclusion
Lower pretreatment SMI was associated with worse long-term survival of bladder cancer patients.
Publisher
Public Library of Science (PLoS)
Reference40 articles.
1. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods;J Ferlay;International journal of cancer,2019
2. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.;H Sung;CA: a cancer journal for clinicians,2021
3. Cancer statistics in China and United States, 2022: profiles, trends, and determinants.;C Xia;Chinese medical journal,2022
4. Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2019.;MJ Kang;Cancer research and treatment,2022
5. Sarcopenia as a prognostic biomarker of advanced urothelial carcinoma.;H Fukushima;PLoS One,2015